Birchview Capital’s Lipocine LPCN Stock Holding History

Birchview Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$893K	Buy	+111,786	New	+$974K	0.51%	43

Other funds holding LPCN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $273M AUM

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Seven Fleet Capital Management Mountain View, California $318M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital's LPCN Position: Q1 2026 in Review

Birchview Capital opened a new position in Lipocine (LPCN) in Q1 2026: 111,786 shares worth $893K. The stake represents 0.51% of the portfolio and ranks #43 among its holdings.

47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

Birchview Capital held 111,786 shares of Lipocine worth $893K as of Q1 2026.
Lipocine was a new Birchview Capital position in Q1 2026.
Lipocine made up 0.51% of Birchview Capital's portfolio in Q1 2026, its #43 holding.
47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.